Traceable metallic antigen release for enhanced cancer immunotherapy
Source abstract
Abstract
Tumor vaccine has shown outstanding advantages and good therapeutic effects in tumor immunotherapy. However, antigens in tumor vaccines can be easily cleared by the reticuloendothelium system in advance, which leads to poor therapeutic effect of tumor vaccines. Moreover, it was still hard to monitor the fate and distribution of antigens. To address these limitations, we synthesized a traceable nanovaccine based on gold nanocluster-labeled antigens and upconversion nanoparticles (UCNPs) for the treatment of melanoma in this study. PH-sensitive Schiff base bond is introduced between UCNPs and gold nanocluster-labeled ovalbumin antigens for monitoring antigens release. Our studies demonstrated that UCNPs conjugated metallic antigen showed excellent biocompatibility, pH-sensitive and therapeutic effect.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanocluster Synthesis and Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Böhme I, Bosserhoff AK (2016) Acidic tumor microenvironment in human melanoma. Pigm Cell Melanoma R 29(5):508–523. https://doi.org/10.1111/pcmr.1249510.1111/pcmr.12495 ↗
2. Briquez PS, Hauert S, Titta A, Gray LT, Alpar AT, Swartz MA et al (2020) Engineering targeting materials for therapeutic cancer vaccines. Front Bioeng Biotechnol 8:19. https://doi.org/10.3389/fbioe.2020.0001910.3389/fbioe.2020.00019 ↗
3. Chen H, Wang FX, Zhang PY, Zhang YL, Chen YX, Fan XH et al (2019) Management of cytokine release syndrome related to CAR-T cell therapy. Front Med 13(5):610–617. https://doi.org/10.1007/s11684-019-0714-810.1007/s11684-019-0714-8 ↗
4. Cheng TJ, Ma RJ, Zhang YM, Ding YX, Liu JJ, Ou HL et al (2015) A surface-adaptive nanocarrier to prolong circulation time and enhance cellular uptake. Chem Commun 51(81):14985–14988. https://doi.org/10.1039/c5cc05854f10.1039/c5cc05854f ↗
5. DeSimone JM (2016) Co-opting Moore’s law: therapeutics, vaccines and interfacially active particles manufactured via PRINT. J Control Release. https://doi.org/10.1016/j.jconrel.2016.07.01910.1016/j.jconrel.2016.07.019 ↗
6. Eisenberg V, Hoogi S, Shamul A, Barliya T, Cohen CJ (2019) T-cells “à la CAR-T(e)” - Genetically engineering T-cell response against cancer. Adv Drug Deliv Rev 141:23–40. https://doi.org/10.1016/j.addr.2019.01.00710.1016/j.addr.2019.01.007 ↗
7. Fan Q, Chen ZP, Wang C, Liu Z (2018) Toward biomaterials for enhancing immune checkpoint blockade therapy. Adv Funct Mater 28(37):1802540–1802564. https://doi.org/10.1002/adfm.20180254010.1002/adfm.201802540 ↗
8. Feng LZ, Dong ZL, Tao DL, Zhang YC, Liu Z (2018) The acidic tumor microenvironment: a target for smart cancer nano-theranostics. Natl Sci Rev 5(2):269–286. https://doi.org/10.1093/nsr/nwx06210.1093/nsr/nwx062 ↗
9. Gao GJ, Turshatov A, Howard IA, Busko D, Joseph R, Hudry D et al (2017) Up-Conversion fluorescent labels for plastic recycling: a review. Adv Sustain Syst 1(5):1600033–1600058. https://doi.org/10.1002/adsu.20160003310.1002/adsu.201600033 ↗
10. Goos JACM, Davydova M, Dilling TR, Cho A, Cornejo MA, Gupta A et al (2020) Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue. Nucl Med Biol 84–85:63–72. https://doi.org/10.1016/j.nucmedbio.2020.02.01210.1016/j.nucmedbio.2020.02.012 ↗
11. Han JY, Zhao DD, Li D, Wang XH, Jin Z, Zhao K (2018) Polymer-based nanomaterials and applications for vaccines and drugs. Polymers 10(1):31–44. https://doi.org/10.3390/polym1001003110.3390/polym10010031 ↗
12. Huang WJ, Lu CH, Jiang CF, Wang W, Song JB, Ni TR et al (2012) Controlled synthesis of NaYF4 nanoparticles and upconversion properties of NaYF4: Yb, Er (Tm)/FC transparent nanocomposite thin films. J Colloid Interf Sci 376(1):34–39. https://doi.org/10.1016/j.jcis.2012.02.04710.1016/j.jcis.2012.02.047 ↗
13. Irvine DJ (2016) Materializing the future of vaccines and immunotherapy. Nat Rev Mater 1(1):15008. https://doi.org/10.1038/natrevmats.2015.810.1038/natrevmats.2015.8 ↗
14. Kraus M, Wolf B (1996) Implications of Acidic Tumor microenvironment for neoplastic growth and cancer treatment: a computer analysis. Tumor Biol 17(3):133–154. https://doi.org/10.1159/00021797710.1159/000217977 ↗
15. Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E et al (2019) Checkpoint blockade immunotherapy induces dynamic changes in PD-1-CD8+ tumor-infiltrating T cells. Immunity 50(1):181–194. https://doi.org/10.1016/j.immuni.2018.11.01410.1016/j.immuni.2018.11.014 ↗
16. Liu XD, Zhang X, Tian G, Yin WY, Yan L, Ruan LF et al (2014) A simple and efficient synthetic route for preparation of NaYF4 upconversion nanoparticles by thermo-decomposition of rare-earth oleates. Cryst Eng Comm 16(25):5650–5661. https://doi.org/10.1039/c4ce00231h10.1039/c4ce00231h ↗
17. Luo XJ, Akimoto K (2013) Upconversion properties in hexagonal-phase NaYF4: Er3+/NaYF4 nanocrystals by off-resonant excitation. Appl Surf Sci 273(15):257–260. https://doi.org/10.1016/j.apsusc.2013.02.02610.1016/j.apsusc.2013.02.026 ↗
18. Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14(8):561–584. https://doi.org/10.1038/nrd459110.1038/nrd4591 ↗
19. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480–489. https://doi.org/10.1038/nature1067310.1038/nature10673 ↗
20. Mi Y, Hagan IVCT, Vincent BG, Wang AZ (2019) Emerging nano-/microapproaches for cancer immunotherapy. Adv Sci 6(6):1801847–1801869. https://doi.org/10.1002/advs.20180184710.1002/advs.201801847 ↗
21. Mohankrishnan A, Patel H, Bhurani V, Parmar R, Yadav N, Dave N et al (2019) Inclusion of Non-target antigen in vaccination favors generation of OVA specific CD4 Memory T cells. Cell Immunol 337:1–14. https://doi.org/10.1016/j.cellimm.2018.11.00510.1016/j.cellimm.2018.11.005 ↗
22. Oliveira H, Bednarkiewicz A, Falk A, Fröhlich E, Lisjak D, Prina-Mello A et al (2019) Critical considerations on the clinical translation of upconversion nanoparticles (UCNPs): recommendations from the European upconversion network (COST Action CM1403). Adv Healthc Mater 8(1):1801233–1801242. https://doi.org/10.1002/adhm.20180123310.1002/adhm.201801233 ↗
23. Rosenberg J, Huang J (2018) CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy. Curr Opin Chem Eng 19:9–20. https://doi.org/10.1016/j.coche.2017.11.00610.1016/j.coche.2017.11.006 ↗
24. Sharipov M, Tawfik SM, Gerelkhuu Z, Huy BT, Lee YI (2017) Phospholipase A2-responsive phosphate micelle-loaded UCNPs for bioimaging of prostate cancer cells. Sci Rep 7(1):16073–16081. https://doi.org/10.1038/s41598-017-16136-410.1038/s41598-017-16136-4 ↗
25. Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Parker Kerrigan BC, Heimberger AB (2017) Tumor vaccines for malignant gliomas. Neurotherapeutics 14(2):345–357. https://doi.org/10.1007/s13311-017-0522-210.1007/s13311-017-0522-2 ↗
26. Tian XN, Jiang GC, Wei XT, Wu LY, Li S, Deng KM et al (2014) Synthesis and photoluminescent properties of NaYF4:Eu3+ core and NaYF4:Eu3+/NaYF4 core/shell nanocrystals. J Nanosci and Nanotechno 14(6):4490–4494. https://doi.org/10.1166/jnn.2014.805310.1166/jnn.2014.8053 ↗
27. Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12(4):237–251. https://doi.org/10.1038/nrc323710.1038/nrc3237 ↗
28. Vormehr M, Türeci Ö, Sahin U (2019) Harnessing tumor mutations for truly individualized cancer vaccines. Annu Rev Med 70(1):395–407. https://doi.org/10.1146/annurev-med-042617-10181610.1146/annurev-med-042617-101816 ↗
29. Vu MN, Kelly HG, Wheatley AK, Peng S, Pilkington EH, Veldhuis NA et al (2020) Cellular interactions of liposomes and pisa nanoparticles during human blood flow in a microvascular network. Samll 2002861. https://doi.org/10.1002/smll.20200286110.1002/smll.202002861 ↗
30. Wang XD, Valiev RR, Ohulchanskyy TY, Ågren H, Yang CH, Chen GY (2017) Dye-sensitized lanthanide-doped upconversion nanoparticles. Chem Soc Rev 46(14):4150–4167. https://doi.org/10.1039/c7cs00053g10.1039/c7cs00053g ↗
31. Wang JM, Hu XB, Xiang DX (2018) Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines. Drug Deliv 25(1):1319–1327. https://doi.org/10.1080/10717544.2018.147785710.1080/10717544.2018.1477857 ↗
32. Wieder T, Eigentler T, Brenner E, Rocken M (2018) Immune checkpoint blockade therapy. J Allergy Clin Immun 142(5):1403–1414. https://doi.org/10.1016/j.jaci.2018.02.04210.1016/j.jaci.2018.02.042 ↗
33. Wu ZF, Xu YB (2010) IL-15Rα-IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor action through NK and CD8+ T cells proliferation and activation. J Mol Cell Biol 2(4):217–222. https://doi.org/10.1093/jmcb/mjq01210.1093/jmcb/mjq012 ↗
34. Xiang J, Xu LG, Gong H, Zhu WW, Wang C, Xu J et al (2015) Antigen-loaded upconversion nanoparticles for dendritic cell stimulation, tracking, and vaccination in dendritic cell-based immunotherapy. ACS Nano 9(6):6401–6411. https://doi.org/10.1021/acsnano.5b0201410.1021/acsnano.5b02014 ↗
35. Yang WJ, Zhu GZ, Wang S, Yu GC, Yang Z, Lin L et al (2019) In situ dendritic cell vaccine for effective cancer immunotherapy. ACS Nano 13(3):3083–3094. https://doi.org/10.1021/acsnano.8b0834610.1021/acsnano.8b08346 ↗
36. Yoshikawa T, Okada N, Oda A, Matsuo K, Matsuo K, Kayamuro H et al (2008) Nanoparticles built by self-assembly of amphiphilic γ-PGA can deliver antigens to antigen-presenting cells with high efficiency: A new tumor-vaccine carrier for eliciting effector T cells. Vaccine 26(10):1303–1313. https://doi.org/10.1016/j.vaccine.2007.12.03710.1016/j.vaccine.2007.12.037 ↗
37. Zhang C, Liu J, Zhong JF, Zhang X (2017) Engineering CAR-T cells. Biomark Res 5(1):22–27. https://doi.org/10.1186/s40364-017-0102-y10.1186/s40364-017-0102-y ↗
38. Zhao JW, Yang H, Li JL, Wang YJ, Wang X (2017) Fabrication of pH-responsive PLGA(UCNPs/DOX) nanocapsules with upconversion luminescence for drug delivery. Sci Rep 7(1):18014–18024. https://doi.org/10.1038/s41598-017-16948-410.1038/s41598-017-16948-4 ↗
39. Zhou XM, Li WQ, Wu YH, Han L, Cao XG, Yang XM et al (2018) Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8+ T cells. Front Immunol 9:2821–2831. https://doi.org/10.3389/fimmu.2018.0282110.3389/fimmu.2018.02821 ↗
40. Zhou B, Li QQ, Yan L, Zhang QY (2020) Controlling upconversion through interfacial energy transfer (IET): fundamentals and applications. J Rare Earths 38(5):474–482. https://doi.org/10.1016/j.jre.2020.01.00910.1016/j.jre.2020.01.009 ↗